Publications by authors named "J Closset"
Article Synopsis
- The study focused on mesopancreatic infiltration in patients with pancreatic ductal adenocarcinoma who had pancreatoduodenectomy, assessing the correlation between imaging findings and histopathology along with their impact on survival.
- A review of 149 patients from 2015 to 2021 showed that solid infiltration of mesopancreatic fat was present in 13.4% of patients, correlating with significantly lower survival rates compared to those with normal fat or fat stranding.
- The results indicate that solid infiltration is a negative prognostic factor for patient survival, with pathological tumor size also playing a critical role in overall and disease-free survival.
Duodenal adenocarcinoma is a rare digestive cancer, often diagnosed at a late stage and harbours a poor prognosis. The arrival of immunotherapy has changed the prognosis of many neoplasia, including digestive adenocarcinomas with MSI-H status. Hereby, we describe three cases of MSI-H locally advanced duodenal adenocarcinoma who received neoadjuvant treatment with a PD1 inhibitor, pembrolizumab.
View Article and Find Full Text PDFBackground: Complete digestive disunion due to anastomotic necrosis is considered a contraindication to endoscopic repair. However, recent publications have suggested that endoscopic treatment by insertion of a self-expandable metal stent (SEMS) is possible. The report of this patient series aims to demonstrate the use of endoscopic management in selected cases with complete digestive disunion.
View Article and Find Full Text PDFBackground: For patients with pancreatic ductal adenocarcinoma (PDAC), surgical resection remains the only potentially curative treatment. Surgery is generally followed by postoperative chemotherapy associated with improved survival, yet neoadjuvant therapy is a rapidly emerging concept requiring to be explored and validated in terms of treatment options and oncological outcomes. In this context, stereotactic body radiation (SBRT) appears feasible and can be safely integrated into a neoadjuvant chemotherapy regimen of modified FOLFIRINOX (mFFX) with promising benefits in terms of R0 resection, local control and survival.
View Article and Find Full Text PDFBackground: Multidisciplinary team (MDT) meetings aim to optimize patient management. We evaluated the impact of MDT discussions on the management and diagnosis of focal pancreatic lesions in a single tertiary center.
Methods: All patients with an initial diagnosis of solid or cystic pancreatic lesion discussed in our institution's MDT meeting on pancreatic diseases between January 1, 2020, and December 31, 2021, were included.